STAT3

Overview

Signal Transducer and Activator of Transcription 3 (STAT3) is a multifunctional transcription factor that serves as a central node in numerous cytokine and growth factor signaling cascades. Upon activation — most characteristically via phosphorylation at Tyrosine 705 (Tyr705) by upstream kinases such as JAKs — STAT3 dimerizes, translocates to the nucleus, and drives transcription of genes governing cell survival, proliferation, differentiation, and immune modulation. Physiologically, STAT3 is activated downstream of cytokines such as interleukin-6 and growth factors including IGF1, making it a critical regulator of tissue homeostasis and inflammation. Its activity is tightly coupled to co-regulatory networks involving pathways such as PI3K/AKT and HIF-1α, underscoring its role as an integrative signal hub.

In disease contexts, STAT3 is one of the most extensively studied oncogenic transcription factors. Aberrant or sustained STAT3 activation has been documented across a broad range of malignancies — including breast cancer, bladder cancer, and hepatic metastatic disease — where it shapes both tumor cell behavior and the surrounding tumor microenvironment. Beyond oncology, STAT3 has emerged as a regulator in fibrotic diseases and in the biology of aging skeletal muscle, reflecting its broad pathophysiological relevance and its attractiveness as a therapeutic target.

Recent Publications Focus

Below is a summary of the newest research publications targeting STAT3 (sorted by publication date).

Recent research demonstrates that STAT3 plays a critical role in multiple cancer-related pathways. In breast cancer, STAT3 emerges as a key hub protein in the acquisition of chemotherapy resistance, particularly in the context of doxorubicin-resistant tumors where exosomal signaling facilitates intercellular transfer of drug resistance [42417926]. Network pharmacology analyses examining cancer therapeutic targets consistently identify STAT3 among the central hub nodes involved in multiple malignancy-related pathways, including those governing apoptosis, immune modulation, oxidative stress, and cell proliferation [42384725]. These findings suggest that STAT3 represents a convergence point for various pro-tumoral mechanisms.

Beyond its role in direct tumor proliferation, STAT3 has emerged as a critical regulator of the tumor microenvironment immune response. In hormone receptor-positive breast cancer, STAT3 phosphorylation at Tyr705 is activated through fibroblast-derived factors IGF1 and FGF7, generated in response to palbociclib therapy, which drives macrophage polarization toward an immunosuppressive M2-like phenotype [41986650]. This STAT3-mediated immunosuppression contributes to reduced lymphocyte viability and represents a previously unrecognized resistance mechanism. Similarly, CD276-enriched exosomes promote tumor progression through STAT3 pathway activation, remodeling the tumor microenvironment to facilitate immune evasion and therapy resistance [41964005].

STAT3 inhibition has shown therapeutic promise in multiple disease contexts beyond cancer. In systemic sclerosis, combined treatment with all-trans retinoic acid and the PPAR-γ agonist rosiglitazone alleviates fibrosis by suppressing the STAT3/Th17 axis [42379744], while in pulmonary fibrosis, modulation of the STAT3/HSP90AA1 pathway by diammonium glycyrrhizinate and vitamin D3 produces synergistic antifibrotic effects [41423159]. Molecular docking and machine learning approaches have identified novel nanomolar inhibitors targeting STAT3 as a therapeutic strategy for cancer [41841313]. These studies collectively indicate that STAT3 suppression or pathway modulation represents a viable intervention strategy across multiple disease states.

STAT3 also functions as a key transcription factor in age-related physiological processes. Bioinformatic analysis of transcriptomic changes induced by caloric restriction and endurance exercise in elderly skeletal muscle identified STAT3 as one of four critical transcription factors governing age-related muscle functional decline [41794155]. These findings suggest that STAT3-mediated signaling extends beyond cancer pathology and fibrotic disease to encompass metabolic and musculoskeletal aging.